Published in Cancer Weekly, March 9th, 2004
This technology is applicable to the development of therapeutics and diagnostics for a broad range of diseases.
Anosys' most advanced, exosome-based program has focused on the development of new cancer therapies. The company has completed a phase I clinical study in the U.S. in patients with advanced non-small cell lung cancer (NSCLC) who have failed current therapies, and a second phase I trial in Europe in advanced melanoma patients. Anosys...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.